CLINICAL TRIALS PROFILE FOR HYPAQUE-M,90%

All Clinical Trials for HYPAQUE-M,90%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	Eli Lilly and Company	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	National University Hospital, Singapore	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00814866 ↗	Bone Resorption, Osteoclastogenesis and Adalimumab	Completed	Abbott	N/A	2008-09-01	Osteoclastic bone resorption depends on both the capacity to generate osteoclasts (osteoclastogenesis) and on individual osteoclast activity. The investigators objective is to study the effect of anti-TNF therapy on the number of osteoclast precursors in the peripheral blood of patients with Rheumatoid Arthritis, on in vitro osteoclastogenesis and on osteoclast activity before and during the treatment of patients with Rheumatoid Arthritis with Adalimumab.
NCT00814866 ↗	Bone Resorption, Osteoclastogenesis and Adalimumab	Completed	Université de Sherbrooke	N/A	2008-09-01	Osteoclastic bone resorption depends on both the capacity to generate osteoclasts (osteoclastogenesis) and on individual osteoclast activity. The investigators objective is to study the effect of anti-TNF therapy on the number of osteoclast precursors in the peripheral blood of patients with Rheumatoid Arthritis, on in vitro osteoclastogenesis and on osteoclast activity before and during the treatment of patients with Rheumatoid Arthritis with Adalimumab.
NCT01234766 ↗	Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma	Completed	Cephalon	Phase 2	2010-10-01	The purpose of the study is to learn about the safety and effectiveness of treating follicular lymphoma with bendamustine and rituximab followed by radioimmunotherapy (RIT) using 90-yttrium (Y) ibritumomab tiuxetan. The researchers will also test blood and bone marrow for the BCL2 gene-Jh that is a commonly found in people with follicular lymphoma (FL) and look at how the BCL2 gene-Jh responds to the study treatment. Bendamustine is approved by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing treatment regimen. Bendamustine is not approved by the FDA to treat follicular lymphoma. Rituximab is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma. 90-yttrium (Y) ibritumomab tiuxetan is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular B-cell NHL, including rituximab refractory follicular NHL. It is also approved for the treatment of follicular NHL that is previously untreated with radioimmunotherapy and that achieved a partial or complete response to first-line chemotherapy. Study participants will will receive bendamustine and rituximab for up to 16 weeks. If participants' cancer responds well to the treatment with bendamustine and rituximab, they will receive up to 12 weeks of radioimmunotherapy (RIT). After the RIT is complete, participants will be asked to return to the clinic every 3 months for a maximum of 10 years for follow-up visits.
NCT01234766 ↗	Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma	Completed	Spectrum Pharmaceuticals, Inc	Phase 2	2010-10-01	The purpose of the study is to learn about the safety and effectiveness of treating follicular lymphoma with bendamustine and rituximab followed by radioimmunotherapy (RIT) using 90-yttrium (Y) ibritumomab tiuxetan. The researchers will also test blood and bone marrow for the BCL2 gene-Jh that is a commonly found in people with follicular lymphoma (FL) and look at how the BCL2 gene-Jh responds to the study treatment. Bendamustine is approved by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing treatment regimen. Bendamustine is not approved by the FDA to treat follicular lymphoma. Rituximab is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma. 90-yttrium (Y) ibritumomab tiuxetan is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular B-cell NHL, including rituximab refractory follicular NHL. It is also approved for the treatment of follicular NHL that is previously untreated with radioimmunotherapy and that achieved a partial or complete response to first-line chemotherapy. Study participants will will receive bendamustine and rituximab for up to 16 weeks. If participants' cancer responds well to the treatment with bendamustine and rituximab, they will receive up to 12 weeks of radioimmunotherapy (RIT). After the RIT is complete, participants will be asked to return to the clinic every 3 months for a maximum of 10 years for follow-up visits.
NCT01234766 ↗	Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma	Completed	Dartmouth-Hitchcock Medical Center	Phase 2	2010-10-01	The purpose of the study is to learn about the safety and effectiveness of treating follicular lymphoma with bendamustine and rituximab followed by radioimmunotherapy (RIT) using 90-yttrium (Y) ibritumomab tiuxetan. The researchers will also test blood and bone marrow for the BCL2 gene-Jh that is a commonly found in people with follicular lymphoma (FL) and look at how the BCL2 gene-Jh responds to the study treatment. Bendamustine is approved by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing treatment regimen. Bendamustine is not approved by the FDA to treat follicular lymphoma. Rituximab is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma. 90-yttrium (Y) ibritumomab tiuxetan is approved by the FDA for the treatment of relapsed or refractory, low-grade or follicular B-cell NHL, including rituximab refractory follicular NHL. It is also approved for the treatment of follicular NHL that is previously untreated with radioimmunotherapy and that achieved a partial or complete response to first-line chemotherapy. Study participants will will receive bendamustine and rituximab for up to 16 weeks. If participants' cancer responds well to the treatment with bendamustine and rituximab, they will receive up to 12 weeks of radioimmunotherapy (RIT). After the RIT is complete, participants will be asked to return to the clinic every 3 months for a maximum of 10 years for follow-up visits.

Clinical Trial Conditions for HYPAQUE-M,90%

Condition Name

Condition Name for HYPAQUE-M,90%
Intervention	Trials
Non Small Cell Lung Cancer	1
Rheumatoid Arthritis	1
Decompensated Cirrhosis	1
Lymphoma, Follicular	1

Condition MeSH

Condition MeSH for HYPAQUE-M,90%
Intervention	Trials
Lymphoma, Follicular	1
Lymphoma	1
Bone Resorption	1
Arthritis, Rheumatoid	1

Clinical Trial Locations for HYPAQUE-M,90%

Trials by Country

Trials by Country for HYPAQUE-M,90%
Location	Trials
United States	4
India	1
Canada	1

Trials by US State

Trials by US State for HYPAQUE-M,90%
Location	Trials
Rhode Island	1
North Carolina	1
New Hampshire	1
Maine	1

Clinical Trial Progress for HYPAQUE-M,90%

Clinical Trial Phase

Clinical Trial Phase for HYPAQUE-M,90%
Clinical Trial Phase	Trials
Phase 2	2
N/A	2

Clinical Trial Status

Clinical Trial Status for HYPAQUE-M,90%
Clinical Trial Phase	Trials
Completed	3
Not yet recruiting	1

Clinical Trial Sponsors for HYPAQUE-M,90%

Sponsor Name

Sponsor Name for HYPAQUE-M,90%
Sponsor	Trials
National University Hospital, Singapore	1
Abbott	1
Université de Sherbrooke	1

Sponsor Type

Sponsor Type for HYPAQUE-M,90%
Sponsor	Trials
Other	4
Industry	4

Last updated: June 14, 2026

HYPAQUE-M 90% (Diatrizoate Meglumine) clinical trials update, market analysis, and market projection

HYPAQUE-M, 90% is a branded iodinated contrast medium (diatrizoate meglumine) used for radiographic imaging. No completed, decision-grade clinical-trial updates (eg, phase, recruiting status, primary completion date, endpoints) or current sales/revenue figures were provided in the request, so a complete clinical-trials and market forecast cannot be produced.

Clinical trials update
No trial registry identifiers (ClinicalTrials.gov/NCT or EU CTR IDs), sponsor names, phase, dosing regimens, or last-update timestamps were provided. A “clinical trials update” specific to HYPAQUE-M, 90% therefore cannot be generated without risking fabrication.

Market analysis and projection
No input data were provided for HYPAQUE-M, 90% such as geography of sales, IMS/IQVIA estimates, unit volumes, pricing, indication mix, channel (hospital vs retail), tender dynamics, competitive set (iohexol, iopamidol, ioversol, iobitridol, metrizamide and other diatrizoate-containing products), or regulatory status (FDA/EMA approvals, label language, procurement constraints). Without those, any projection would be speculative.

What clinical trials exist for HYPAQUE-M 90% and when are they expected to finish?

Featured snippet answer: Not determinable from the provided information.

Which registry should be checked first for HYPAQUE-M 90% studies?

Featured snippet answer: ClinicalTrials.gov (and EU Clinical Trials Register) but no identifiers were supplied.

How big is the iodinated contrast media market for HYPAQUE-M 90% and what share does it hold?

Featured snippet answer: Not determinable from the provided information.

How do diatrizoate meglumine products compete vs nonionic, low-osmolar contrast agents?

Featured snippet answer: Not determinable from the provided information.

Which hospitals and radiology groups drive procurement for diatrizoate meglumine in key regions?

Featured snippet answer: Not determinable from the provided information.

When does HYPAQUE-M 90% face supply, pricing, or reimbursement headwinds?

Featured snippet answer: Not determinable from the provided information.

How do tender cycles affect volumes for older contrast chemistries like diatrizoate?

Featured snippet answer: Not determinable from the provided information.

What is the forecast for HYPAQUE-M 90% volume and revenue through 2028–2032?

Featured snippet answer: Not determinable from the provided information.

What scenario model inputs are required for contrast media projections?

• Baseline unit volumes and price per unit (by geography)
• Hospital penetration and tender win rates
• Switching rate versus alternative contrast agents
• Regulatory and supply continuity (manufacturing capacity, disruptions)
• FX and import cost pass-through

Key Takeaways

• A decision-grade clinical trials update for HYPAQUE-M, 90% requires registry-linked trial details (phase, endpoints, completion dates). None were provided.
• A defensible market analysis and multi-year projection requires baseline sales, unit volumes, geography, pricing, competitive set, and regulatory status. None were provided.
• No actionable forecast or competitive/clinical risk assessment can be produced from the information available in the request.

FAQs

1. What are HYPAQUE-M 90% indications and how do they map to modern contrast protocols?
2. Are HYPAQUE-M 90% products approved by the FDA or EMA, and what label restrictions apply?
3. Does HYPAQUE-M 90% have ongoing or planned phase 3 studies in any region?
4. How does diatrizoate meglumine pricing typically move relative to nonionic low-osmolar contrast agents?
5. What are the main safety considerations for iodinated contrast that influence purchasing decisions?